Genmab Achieves USD 25 Million Sales Milestone in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
260
Genmab Achieves USD 25 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen

Company Announcement

  • First sales volume milestone reached in DARZALEX (daratumumab) collaboration with Janssen
  • Genmab to receive milestone payment of USD 25 million

Copenhagen, Denmark; January 6, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that it has achieved the first sales volume milestone in its DARZALEX ® (daratumumab) collaboration with Janssen. The USD 25 million milestone was triggered by sales of DARZALEX reaching USD 500 million in a calendar year. In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize DARZALEX.

“We have seen an extremely robust launch of DARZALEX since its approval in the U.S in November 2015 and in Europe in May 2016, with very rapid sales uptake. We are very pleased to receive the first commercial sales volume milestone so quickly,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

The milestone payment was included in Genmab’s financial guidance published on December 20, 2016.

About DARZALEX ® (daratumumab) DARZALEX ® (daratumumab) injection for intravenous infusion is indicated in the United States in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent. 1 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (FDA) approval to treat multiple myeloma. DARZALEX is indicated in Europe for use as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.  For more information, visit www.DARZALEX.com .  

Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells .   Daratumumab triggers a person’s own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death). 1,2,3,4,5

Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. Five Phase III clinical studies with daratumumab in relapsed and frontline multiple myeloma settings are currently ongoing, and additional studies are ongoing or planned to assess its potential in other malignant and pre-malignant diseases on which CD38 is expressed, such as smoldering myeloma, non-Hodgkin’s lymphoma, NKT-cell lymphoma, amyloidosis, Myelodysplastic Syndromes and solid tumors.  Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA, for multiple myeloma, as both a monotherapy and in combination with other therapies.  

About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications, non-Hodgkin’s lymphoma and solid tumors.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com . Contact:           Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo ® ; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody ® and UniBody ® . Arzerra ® is a trademark of Novartis AG or its affiliates. DARZALEX ® is a trademark of Janssen Biotech, Inc.

1 F DA 2015. Daratumumab Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs...lbledt.pdf. Last accessed December 2016 .

2 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848. 3 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21. 4 Krejcik, MD et al. Daratumumab Depletes CD38+ Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94. 5 Jansen, JH  et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. Blood. 2012;120(21):abstract 2974.

Company Announcement no. 01 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Genmab A/S Bredgade 34E 1260 Copenhagen K Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 151

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 109

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 43

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
DEFSEC Completes 9-to-1 Share Consolidation

Updated Category News Views 16

DEFSEC Technologies Tightens the Belt So, DEFSEC Technologies just pulled off something that'll kick up dust among investors. A 9-to-1 share consolidation—now that's no small fry. For those riding the NASDAQ or the TSX Venture with a tight grip on their DEFSEC shares, it's strictly business today. Post-consolidation, DEFSEC's common shares are set to trade under the...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 21

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 17

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
VIO Med Spa’s Black Friday Event: Aesthetic Savings

Updated Category News Views 34

Kicking Off the Holiday Season with a Glow Just when you think the holiday hustle can't get busier, VIO Med Spa is opening the gates of rejuvenation just in time to add yourself to that epic list. Starting November 16, VIO launches its Black Friday extravaganza—a deal-laden kick-off that means smooth skin and sharper looks are up for grabs. Member Benefits and Public...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 24

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 49

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 362

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating a Milestone: Gifting the 400th Home to a Veteran

Updated Category News Views 339

Celebrating a Milestone with 400th Home Gift Building Homes for Heroes and Hillwood Properties proudly partnered to celebrate a significant milestone by gifting a home to U.S. Army Specialist Joshua Sager and his family. This remarkable achievement signifies the organization’s commitment to providing veterans and first responders with the means to establish a fresh...

Continue Reading
Wheeler REIT Achieves Record Price as Growth Continues

Updated Category News Views 259

Wheeler REIT Reaches New Milestone In an extraordinary demonstration of resilience and upward momentum, Wheeler Real Estate Investment Trust (WHLRD) has achieved a remarkable milestone by hitting a 52-week high of $27.49 USD. This achievement reflects the company's strong performance and investor confidence in its strategic direction. Strong Financial Position Recent data...

Continue Reading
S&P Global Splits Off Mobility Unit: Investor View

Updated Category News Views 52

Strategic Moves Shake Up S&P Global Listen up, traders! You don’t want to miss what S&P Global, ticker NYSE:SPGI, is cooking up. They've given the green light to split off their Mobility division, officially birthing Mobility Global Inc. This shake-up promises to stir some excitement in the market. Buckle up, because here's what this movement means for you and your...

Continue Reading
Carvana's Q3 Earnings Surge Promises Bright Future for CVNA

Updated Category News Views 103

Carvana Shares Soar After Impressive Q3 Earnings Report Recently, Carvana (NYSE: CVNA), a leading online used-car retailer, experienced a significant surge in its stock price as a result of a positive earnings announcement for the third quarter. The encouraging outlook provided by the company has delighted investors, pushing shares upward during premarket trading....

Continue Reading
PHINIA Unveils Comprehensive Guide to International Emission Standards

Updated Category News Views 150

PHINIA Unveils New Emission Standards Guide for 2024/25 PHINIA Inc. (NYSE: PHIN), a leading name in premium fuel systems and electrical solutions, has launched its latest 2024/25 Emission Standards Booklet specifically designed for heavy-duty and off-road vehicles, engines, and machinery. This guide is unique as it serves as the only complete resource available to keep...

Continue Reading